Abstract
Recent studies demonstrate that calcium antagonists, such as bepridil and verapamil, enter and accumulate in muscle cells, and suggest that these drugs may have intracellular effects in addition to their role as inhibitors of the slow inward Ca2+ current (1,2). Therefore, we have tested a group of calcium “slow channel” blockers for their ability to inhibit human platelet aggregation, which requires extracellular Ca2+, and the activity of human platelet phospholipase A2,an enzyme that is calcium-dependent and is associated with intracellular membranes (3,4). All the calcium antagonists tested, except nifedipine, inhibited ADP-induced aggregation of human platelets. The extent of inhibition by a given concentration of bepridil increased with the time of preincubation with drug. D-600 and diltiazem were the most potent inhibitors of aggregation. Human platelet phospholipase A2 activity was maximally active at pH 7.0 and had an absolute requirement for, and was extremely sensitive to, low concentrations of CaCl2. Activity was stimulated 220% by 10-7 M D-600, was inhibited to different degrees by bepridil, nitrendipine, and verapamil, and was essentially unaffected by nifedipine, mesudipine, and higher concentrations of D-600. Inhibition of phospholipase A2 activity by bepridil was relieved by increasing concentrations of CaCl9. Bepridil, verapamil, and propranolol displaced 45Ca from the membranes of autoclaved E. coli. The differential effects of these calcium antagonists on human platelet phospholipase A2 activity suggest that these drugs may produce secondary effects inside the cell.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Vogel S, Crampton R, Sperelakis N: Blockade of myocardial slow channels by bepridil (CERM-1978). J. Pharmacol. Exp. Ther. (210): 378–385, 1979.
Pang D, Sperelakis N: Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscle. Eur. J. Pharm. (87): 199–207, 1983.
Trugnan G, Bereziat G, Manier MC, Polonovski J: Phospholipase activities in subcellular fractions of human platelets. Biochim. Biophys. Acta (573): 61–72, 1979.
Jesse R, Franson R: Modulation of purified phospholipase A« activity from human platelets by calcium and indomethacin. Biochim. Biophys. Acta (575): 467–470, 1979.
Fleckenstein A: Specific pharmacology of calcium in the myocardium, cardiac pacemakers and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol (17): 149–166, 1977.
Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y: Inhibition of human platelet functions by verapamil. Thrombos. Haemostas. (45): 158–161, 1981.
Born GVR, Cross MJ: The aggregation of blood platelets. J. Physiol. (168): 178–195, 1963.
Thakkar J, Sperelakis N, Pang D, Franson R: Characterization of phospholipase A9 activity in rat aorta smooth muscle cells. Biochim. Biophys. Acta (750): 134–140, 1983.
Franson R, Weir D, Thakkar J: Solubilization and characterization of a neutral-active and calcium-dependent, phospholipase A9 from rabbit heart and isolated chick embryo myocytes. J. Mol. Cell Cardiol. (15): 189–196, 1983.
Bligh EG, Dyer WJ: A rapid method for total lipid extraction. Can. J. Physiol. (37): 911–917, 1959.
Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal. Biochem. (72): 248–254, 1976.
Zucker MB, Grant RA: Nonreversible loss of platelet aggregation by calcium deprivation. Blood (52): 505–514, 1978.
Mras S, Sperelakis N: Bepridil (CERM-1978) and verapamil depression of contractions of rabbit aortic rings. Blood Vessels (18): 196–205, 1981.
Franson R, Weir D: Isolation and characterization of a membrane- associated, calcium dependent phospholipase A2 from rabbit lung. Lung (160): 275–284, 1982.
Franson R: Intracellular metabolism of ingested phospholipids. In Knight G (ed) Liposomes from physical structure to therapeutic applications. Elsevier North Holland, 1981, pp. 349–380.
Kunze N, Nahas N, Trenor J, Wurl M: Effects of local anesthetics in phospholipases. Biochim. Biophys. Acta (441): 93–102, 1976.
Franson R, Eisen D, Jesse R, Lanni C: Inhibition of highly purified mammalian phospholipases A? by nonsteroidal antiinflammatory agents. Biochem. J. (186): 633–636, 1980.
Hauser G, Pappu AS: Effects of propranolol and other cationic amphiphilic drugs on phospholipid metabolism. In: Horrocks L, Ansell G, Bocellati G (ed) Phospholipids in the nervous system. Raven Press, New York, 1982, pp. 283–300.
Singh J, Babcock D, Lardy H: Induction of accelerated acrosome reaction in guinea pig sperm. Biol. Reprod. (22): 566–570, 1980.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Franson, R.C., Evans, H., Thakkar, J., Sperelakis, N. (1984). Inhibition of Human Platelet Aggregation and Calcium-Dependent, Phospholipase A2 Activity by Calcium Antagonists: Evidence for Intracellular Effects of Calcium Slow Channel Blockers. In: Sperelakis, N., Caulfield, J.B. (eds) Calcium Antagonists. Developments in Cardiovascular Medicine, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3810-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3810-9_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3812-3
Online ISBN: 978-1-4613-3810-9
eBook Packages: Springer Book Archive